Skip to Content
Merck
  • Curcumin enhances LXRα in an AMP-activated protein kinase-dependent manner in human macrophages.

Curcumin enhances LXRα in an AMP-activated protein kinase-dependent manner in human macrophages.

The Journal of nutritional biochemistry (2017-12-16)
Javier Sáenz, Gonzalo Alba, María E Reyes-Quiroz, Isabel Geniz, Juan Jiménez, Francisco Sobrino, Consuelo Santa-María
ABSTRACT

Liver X receptor alpha (LXRα) is a nuclear receptor involved in cholesterol homeostasis. Curcumin, a traditional Chinese derivative from the rhizomes of Curcuma longa and a well-known AMP-activated protein kinase (AMPK) activator, possess hypocholesterolemic activity, however, the possible link between AMPK and cholesterol is unknown. In this study, we have investigated whether curcumin regulates metabolic changes in cholesterol metabolism via LXRα in THP-1 human macrophages, the cells implicated in atheroma plaques formation. Results showed that curcumin induced AMPK phosphorylation, increased LXRα mRNA and protein expression. Curcumin up-regulated mRNA expression of genes involved in cholesterol transport and metabolism as ATP-binding cassette (ABC) transporters ABCA1 and ABCG1, and the sterol response element binding protein 1c (SREBP1c). On the other hand, this increased LXRα mRNA and protein expression was reverted when AMPK was inhibited by its chemical inhibitor, compound C. Transfection with AMPK α1 and α2 siRNA decreased the LXRα mRNA expression and its target genes. Curcumin treatment inhibited cell migration and was also able to promote reverse cholesterol transport in THP-1 cells. This enhanced reverse cholesterol transport might be related to the up-regulating of ABCA1 and ABCG1 mRNA expression by activating AMPK-LXRα signaling in THP-1 cells. This study describes a possible mechanism for understanding the hypocholesterolemic effects of curcumin and expand knowledge about the LXRα regulation by AMPK.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Dorsomorphin, ≥98% (HPLC)
Sigma-Aldrich
Pentostatin, ≥95% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human PRKAA1